Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
A cautious approach for now is warranted as well as a need for a randomized clinical trial.
For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
Paul Offit, MD, offers a glimpse of when the outbreak might end as well as where we are with herd immunity, the MMR vaccine’s efficacy, and insights on breakthrough cases.
With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.
American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.
This bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.
Joseph Cherabie MD, MSc, explains the importance of how these 2 components go hand-in-hand, and what it means to continue forward in spite of being in an unpredictable time.
Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.
Kate Broderick, PhD, molecular geneticist, discusses the mRNA capping technology and how it helps create stability to mRNA molecules within vaccines and guides them to cells.
Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
Buddy Creech, MD, MPH, assures that the interim findings of the study indicate adolescents produced a stronger immune response compared to adults, with minimal adverse effects.
The evolution of the major variants, including the delta mutation.
Understanding the potential and limitations of new Acinetobacter baumannii active therapies.
Can duration of therapy requirements at the time of antibiotic order entry decrease antibiotic use?
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
Matthew Hepburn, MD, offers some insights on his time as vaccine development lead for Operation Warp Speed and the ability to develop a COVID-19 vaccine within a year.
Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.
In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.